Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/35774
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Viron, Sylviane-
dc.contributor.authorTrotta, Laura-
dc.contributor.authorSchumacher, Helmut-
dc.contributor.authorLomp, Hans-Juergen-
dc.contributor.authorHoppner, Sebastiaan-
dc.contributor.authorYoung, Steve-
dc.contributor.authorBUYSE, Marc-
dc.date.accessioned2021-11-05T11:57:02Z-
dc.date.available2021-11-05T11:57:02Z-
dc.date.issued2022-
dc.date.submitted2021-10-28T13:07:48Z-
dc.identifier.citationTherapeutic Innovation and Regulatory Science, 56, p. 130-136-
dc.identifier.urihttp://hdl.handle.net/1942/35774-
dc.description.abstractBackground A central statistical assessment of the quality of data collected in clinical trials can improve the quality and efficiency of sponsor oversight of clinical investigations. Material and Methods The database of a large randomized clinical trial with known fraud was reanalyzed with a view to identifying, using only statistical monitoring techniques, the center where fraud had been confirmed. The analysis was conducted with an unsupervised statistical monitoring software using mixed-effects statistical models. The statistical analyst was unaware of the location, nature, and extent of the fraud. Results Five centers were detected as atypical, including the center with known fraud (which was ranked 2). An incremental analysis showed that the center with known fraud could have been detected after only 25% of its data had been reported. Conclusion An unsupervised approach to central monitoring, using mixed-effects statistical models, is effective at detecting centers with fraud or other data anomalies in clinical trials.-
dc.language.isoen-
dc.publisherSPRINGER HEIDELBERG-
dc.rightsThe Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.-
dc.subject.otherStatistical monitoring-
dc.subject.otherCentral monitoring-
dc.subject.otherRisk-based monitoring-
dc.subject.otherFraud-
dc.subject.otherMisconduct-
dc.titleDetection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring-
dc.typeJournal Contribution-
dc.identifier.epage136-
dc.identifier.spage130-
dc.identifier.volume56-
local.format.pages7-
local.bibliographicCitation.jcatA1-
dc.description.notesDe Viron, S (corresponding author), CluePoints SA, Ave Albert Einstein,2a, B-1348 Louvain La Neuve, Belgium.-
dc.description.notessylviane.deviron@CluePoints.com-
local.publisher.placeTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1007/s43441-021-00341-5-
dc.identifier.pmid34590286-
dc.identifier.isiWOS:000701359000001-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[de Viron, Sylviane; Trotta, Laura; Hoppner, Sebastiaan; Buyse, Marc] CluePoints SA, Ave Albert Einstein,2a, B-1348 Louvain La Neuve, Belgium.-
local.description.affiliation[Lomp, Hans-Juergen] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany.-
local.description.affiliation[Young, Steve] CluePoints Inc, King Of Prussia, PA USA.-
local.description.affiliation[Buyse, Marc] Int Drug Dev Inst IDDI, Louvain La Neuve, Belgium.-
local.description.affiliation[Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Hasselt, Belgium.-
local.uhasselt.internationalyes-
item.accessRightsOpen Access-
item.contributorde Viron, Sylviane-
item.contributorTrotta, Laura-
item.contributorSchumacher, Helmut-
item.contributorLomp, Hans-Juergen-
item.contributorHoppner, Sebastiaan-
item.contributorYoung, Steve-
item.contributorBUYSE, Marc-
item.validationecoom 2023-
item.fullcitationde Viron, Sylviane; Trotta, Laura; Schumacher, Helmut; Lomp, Hans-Juergen; Hoppner, Sebastiaan; Young, Steve & BUYSE, Marc (2022) Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring. In: Therapeutic Innovation and Regulatory Science, 56, p. 130-136.-
item.fulltextWith Fulltext-
crisitem.journal.issn2168-4790-
crisitem.journal.eissn2168-4804-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
s43441-021-00341-5.pdfPublished version603.45 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.